Panacea Biotec has strengthened its vaccine order pipeline after UNICEF revised and expanded its existing supply contract for the WHO pre-qualified pentavalent vaccine, Easyfive-TT (DTwP-HepB-Hib). This agreement covers the 2023–2027 period. The update includes higher-order values for the later years of the agreement. Additionally, it includes a fresh award for 2027.

Under the revised terms, the contract value for 2026 has increased by $2.55 million, bringing the total to $16.8 million. This amount is roughly Rs 23 crore higher than earlier. For 2027, the contract value has gone up by $2.70 million to $15.18 million. This translates to an additional Rs 24 crore. Apart from this increase, Panacea Biotech has also secured a fresh vaccine award for 2027 worth $3.68 million, or about Rs 33 crore.

Earlier in October, UNICEF had placed another major order with the company for polio vaccines. Panacea Biotech received a letter of award under a long-term agreement to supply bivalent oral polio vaccine (bOPV) in 10-vial and 20-vial packs. This supply contract will run from 1st April 2026 to 31st March 2030. Consequently, it further strengthens the company’s vaccine order book from the UN agency.

Currently, the company’s market capitalisation stands at around Rs 2,199 crore.

Ready to invest like a pro? Tradz by EquityPandit equips you with 100+ Free tools and knowledge you need to succeed. Download the Tradz app and gain access to daily stock lists and insightful market analysis and much more!